AstraZeneca PLC (LON:AZN) said its heart failure drug Farxiga has received a sign-off from the US Food & Drug Administration (FDA).
The treatment has been shown to reduce the risk of death and hospitalisation for cardiovascular patients with a condition called reduced ejection fraction.
The green light follows the granting of fast-track status for the AstraZeneca discovery.
“With the approval of Farxiga, we have reached a critical milestone to potentially transform heart failure treatment for the millions of people living with the condition in the US,” Mene Pangalos, vice-president of bio-pharmaceuticals R&D at the Anglo-Swedish giant said in a sxtatement.
“We are now one step closer to making a significant impact on their lives by providing a much-needed treatment to help reduce their disease burden and live longer."